Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just caught your pvt message from 6 months ago. You are an idiot.
Nice investigative work, Mr. Riley. If there's a Greg Palast Award for message board poster, you would be tough to beat.
Diluting 700m shares by 2.2m more is gonna kill us. Bankruptcy court here we comr.
I think that was lifted from the clinicaltrials.gov readout. My thought was that the endpoints provided narrow criteria for "efficacy," when considering all the data compiled with previous trials. Between the FDA's corruption and BP influence, Trump's pressure with Election Day looming, the dire urgency of a treatment as we head into the flu season and potential spike, media bias and hints of Nader's aggressiveness wearing thin on decision makers, not to mention him thumbing his nose at the powerful BP bloc's lowball buyout efforts, according to reports, it's a nervous time. Just keep chanting, "it's the science, it's the science ..." until CD12 results are reported next month and everything will be OK. Maybe.
Yeah, hope not, but if they do the UK should start their enrollment soon.
I'm concerned the CD12 trial won't be enough for FDA to approve EUA because the only measurement being counted is mortality. Nothing for viral load suppression, oxy saturation, or anything else. Does this concern you as well?
When you surround yourself with yes-men, lackeys, unqualified advisers and cabinet selections and corporate tools, with a leader way out of his element, you get a gubmint even more dysfunctional than the last. And waiting in the wings is a bumbling, dementia-ridden failure on many levels ... man, we need approval and trip-digit PPS so we can go into seclusion.
I never knew that Onion - and neither did my brother who got regular interferon tx for Hep B until he passed from liver cancer complications. We knew it could cause liver damage, but he never mentioned myelin disintegration. He was probably never advised, as you said.
SAEs on top of SAEs. What a horrible way to deteriorate.
For good reason, Jimmy. That is a frightening thought. I didn't know that was passed, but I know it's been a repub/mcconnell sticking point in stimulus negotiations.
Yeah, that scenario sounds more likely than my wishful thinking.
No doubt he'll be doing interviews while the MHRA meeting is going on or maybe as they prepare ... "here's our team as we go into meeting with UK just before they approve us." Interviews are of course at the top of the list with all this going on. Debunked.
he's the only bearer of negative news, especially when no news is circulating. Back up to $5 negates his input. $5.95 wasted BP money again!!
According to news report, rupture of myelin, the protective sheath around spinal column is reason for halt. Report said this may be the second such incident. I'm not an expert, but I do understand this is critical protection ... could this knock their vax candidate out of the game entirely?
DOW down 500 points; CYDY up 50 cents. Duh facts seem to be saying it's a hopeless situation to be stuck on the short bus holding tickets for the team ready to cure covid! What a sad crowd to be clammed up with. Will they get off at the next stop and grab a ticket for the promised land beyond the 10th floor, or will they go down with the terminal bus? Everybody on board! Going up!!
Approving a drug for M2M treatment with NO clinical trials done on that population is NOT how doing their job is defined. Same goes for untested Convoluted Plasma as far as being evaluated in double-blind, placebo vs. drug trials. Leronlimab HAS succeeded in m2m trials, besting remdesivir in both safety and efficacy, so who you shilling for dopester?
Approving weak or unproven treatments like convoluted plasma and remdesivir is how you define doing their jobs? I thought their jobs were to evaluate all treatments thoroughly before approval and not play favorites with big money pharmas? I guess you have a different opinion.
Didn't know that Monroe. Thanks for the info.
The EU approval for EUA would include the last three and many more. Only the UK is out of the EU in Europe I think, unless Greece got the bum's rush.
I bet he will play the victim to the alleged "deep state" that really only exists in his "shallow state" of cognitive awareness. At least he can tell the difference between an elephant and a donkey. He did pass that exam, correct?
My sources at splatt and Shitron news say Nader dumped the shares. Can't confirm ...
Once his enema is done, the first draft will be available.
Contrary to biased opinion, I think the 50m shares are to serve as a deterrent of a hostile takeover for this extremely valuable, game-changer of a product.
Semantics aside, they are still not established without any approved products to market, a skeleton staff and still looking for a win vs. FDA and the simple point I tried to make was these kinds of minor stumbles along the way are frequent with companies at this stage of development. If the results continue to be superior to the competition, these little missteps will be long forgotten and prove to be very insignificant in the long haul, even if it takes a few more months to get to approval. You seem to be way too keenly focused on the minutiae.
100m shares they can use for an offering already approved.
I think some people forget that startup bios with small staffs and shallow pockets typically screw things up their first times thru the process. Limited cash prevents having advisory staffs for guidance and well-placed lobbyists/insiders/PR people out front pushing their product to the bribe collection committee, or whoever polices the fast track, so we're stuck taking the slower path to approval. Desperate times could be an advantage if they don't get lost in the huge pack trying to accomplish the same thing.
Israel was on the original list of five countries that NP was submitting EUA applications to, but a day or two later Israel was left off and I think the Philippines emerged as one of the targets. Many of our closest allies, UK and Israel for two, bend over for uncle sam when pushed. If BP is pushing to suppress LL, as the steady flow of media hit pieces suggest, would they put that big thumb of their heavy hand to tip the scales to their liking? If these countries are willing to back us in meaningless wars for profit and imperialist designs, why not sell out for a lousy EUA drug approval?
I understand how our monopolized media works all too well with my background in journalism. They control and manipulate the news/message/topics of discussion we hear to placate their advertisers that either keep them afloat or awash in riches, in particular, the big three so-called news outlets. The money factor is why these journalistic sewers never have a fair discussion on the merits of a universal health care system that would work so much better than our health care system, if implemented properly, or why every democratic nation has it except the US. Or why they never question the never-ending useless wars for profit. It's the knowledge from this background that prompts my fears that the FDA will allow BP to throttle this company until they can steal it for a song. And the leverage the US often exerts on its "allies" to comply with their wishes will stand in the way of getting an EUA overseas. If the UK/EU is willing to subvert the law to hold Julian Assange hostage on flimsy charges to please the US who want to destroy him for exposing war crimes, then why wouldn't they also be willing to suppress EUA approval for LL to placate BP? Is that heavy-handedness behind the reason why the inclusion of US #1 puppet Israel in the EUA submissions was there one day and gone the next? I don't know how else to explain why a drug like LL with a stellar safety profile is not RUSHED into EUA during a pandemic that demands every potential safe treatment be made available. How long did it take Remdesivir? 2 days after submission? From rigged elections to paramilitary cops rampaging on the streets like a third-world totalitarian state to monopolization of every sector of the economy worth monopolizing, I don't trust this US of A Inc. to do right by its people when big fat bribes are on the table urging them to do otherwise. I'm gambling that lernolimab will prevail someday and bust thru the iron curtain of plutocracy that is destroying this country from within, but I'm as nervous as a hooker in church about it, as an old friend likes to say. Hope I haven't gotten too political here for the message board police, but politics plays a big role in the future of this treatment and our investment and needs to be discussed IMO.
We sure wouldn't want liars to prosper, would we?
NP also said their attys are looking into the matter. You'd think a libel suit would make these cockroach reporters scatter like citron's andrew LEFT the scene.
That was part of their disclaimer in the opening remarks. Don't hold us accountable period, I mean for omissions, or anything else we screw up. Does that disclaimer come with all prescriptions they fill? Pharmacists abandon accuracy in rush to release ... guidelines for other pharmacists? Third-world dumpster fire, he we come!! Leadership stfarts at the top. Or doesn't.
Yeah, agreed. I'm glad this never came to fruition. Why tarnish your stellar safety profile by mixing it with some toxic sh** like Remdesivir? You'd think with the safety record we have that the FDA would be dragging us in the door for EUA. There's no risk and no reason for even a REMS to be considered.
I cringed thru that story catching the awful reporting, but I guess Fox didn't build its empire on facts. And she's a Doctor? She should know that you can't enroll for P3 trials when P1 results are still unknown, or even P2. Thanks for crappin' all over our good news, doc.
I don't see any SEC filings for this company, no help on their website and a confusing financial statement with Swiss version of the info on the company homepage. Can anyone lead me to a site where I can learn more about the financial status like you'd find in the quarterly reports?
And then it was blurred out and unavailable on forbes site. Kinda odd, huh?
I'd like to know. Could it be that Mr. Landstreet says emphatically that "it's LL" that will be the focus of trump's address tonight and soon after the wapo and a couple others reported the focus is definitely on plasma? Or did a BP advertiser threaten to leave?
Here ya go, JDMB and everyone else behind the iron curtain of forbes: There Really Is A Covid Therapy That Works. It’s Called Leronlimab.
Thomas LandstreetContributor
Markets
Imagine if Covid-19 was just a bad cold. 176,000 Americans might not have died. We would not have destroyed the economy. Twenty million Americans would not have lost their jobs or shut their businesses. Debt and deficits would not be exploding – putting generations at risk. Covid-19 needs to go away but a vaccine might not be the answer to our emergency. We need an effective treatment now, one that reduces Covid-19 to a common cold. CytoDyn’s molecule, Leronlimab, does just that.
Vaccines, which are all the talk, might not be around the corner. There is still no HIV/AIDS vaccine after huge sums of money spent by the government. Now the government is spending huge sums of money again in search of a Covid vaccine. One might eventually emerge but when it does, production has to be scaled up because most people will need to take it…repeatedly. And the vaccine maker will somehow need to account for the fact that the virus mutates. That all represents a very long and complicated process that ultimately, may or may not work.
Leronlimab is a monoclonal antibody knocking on the door of an Emergency Use Authorization (EUA) from the FDA. President Trump has scheduled a press conference today to announce a “breakthrough” therapy. It has to be Leronlimab whose owner, CytoDyn (CYDY) just presented favorable data from a double blinded placebo controlled study. It is the only drug to have done so. The drug showed efficacy and safety in a difficult population to address: mild to moderate patients. So while Gilead’s (GILD) Remdesivir (the only other drug with an EUA for Covid), remains controversial, there’s an opening for something better and Leronlimab certainly is that.
Leronlimab has the coolest sounding function: it calms the cytokine storm. As you probably know, the Covid-19 virus is not as bad for you as your body’s immune response to it. It sets off a reaction that gets out of control, especially in the lungs. The virus invades the body infecting, injuring and killing cells. This causes infection. The injured cells scream “help” by releasing cytokines. Cytokines summon chemokines which rush to fight the infection but this causes more infection in a vicious cycle. In severe Covid disease, a “cytokine storm” takes place in the lungs causing acute respiratory distress syndrome. Leronlimab calms the cytokine storm and it does so in three days. It has proven to be a life saver. If approved, it will also save the economy.
Leronlimab is an injectable – a subcutaneous shot, like insulin – which means it can be administered in an outpatient setting, without a hospital stay. In the trial it stopped mild to moderate patients from getting worse, dramatically accelerating their time to recovery. Plus, there’s an adequate supply to meet current demand. Gilead’s Remdesivir has unsavory side effects, nebulous efficacy and requires an IV and a hospital admission. Its side effects alone are enough to prevent broad use.
CytoDyn is an underdog, rarely mentioned in the press, while the government behaves like a child in a scary movie throwing billions of dollars at politically connected pharmaceutical companies. A feeding frenzy has developed as “promising” vaccines and treatments vie for attention from the government and investors. In May, Moderna (MRNA) launched a press release announcing partial, unsubstantiated results from a trial sending the stock soaring and insiders selling. Gilead has eight paid consultants on the scientific advisory committee assembled to help the government form a Covid response.
Meanwhile, obscure, OTC-listed CytoDyn has a dramatic immediate future as it expects a FDA decision on the Emergency Use Authorization any day now. Trump has foreshadowed today’s presser describing a therapy just like Leronlimab (An HIV drug administered by shot with results within three days). The largest company on the fringe OTC market, CytoDyn, hopes to be able to “uplist” on the Nasdaq NDAQ within the next couple of weeks.
Let’s hope it happens. Leronlimab works and we need it now.
Get the best of Forbes to your inbox with the latest insights from experts across the globe.
forbes just updated their glowing article on CYDY by Thomas Landstreet: it's now blurred out! https://www.forbes.com/sites/thomaslandstreet/2020/08/23/there-really-is-a-covid-therapy-that-works-its-called-leronlimab/amp/
With everything else he's promoted to be proven weak or totally ineffective, putting to much hope on him to recognize the benefits of LL is a big leap of faith.